La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Arbutus Biopharma a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Arbutus Biopharma..

Arbutus Biopharma (NASDAQ:ABUS) Azioni, Catena delle Opzioni

Arbutus Biopharma

Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.

Arbutus Biopharma Corporation - Common Stock

Arbutus Biopharma Corp

Dynatrace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DT#NYSE">DT</a>) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $61.88, a high estimate of $65.00, and a low estimate of $52.00. This current average reflects an increase of 8.56% from the previous average price target of $57.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1731081636_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of Dynatrace by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Colville</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$62.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Blair Abernethy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Pinjalim Bora</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$60.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Gray Powell</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$63.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Brent Thill</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$65.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Andrew DeGasperi</td>
<td>Exane BNP Paribas</td>
<td>Announces</td>
<td>Neutral</td>
<td>$52.00</td>
<td>-</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$64.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>John Difucci</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$64.00</td>
<td>$55.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Dynatrace. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Dynatrace compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Dynatrace's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Dynatrace's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/DT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Dynatrace analyst ratings.</a>
<h2>Discovering Dynatrace: A Closer Look</h2>
Dynatrace is a cloud-native company that focuses on analyzing machine data. Its product portfolio, delivered as software as a service, allows a client to monitor and analyze its entire IT infrastructure. Dynatrace's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to use it for a variety of applications throughout their businesses.
<h3>A Deep Dive into Dynatrace's Financials</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Dynatrace displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 19.93%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: Dynatrace's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 9.67% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Dynatrace's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 1.89%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Dynatrace's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 1.16%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Dynatrace's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.04.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Key Takeaways From Dynatrace Analyst Ratings

Barrington Research analyst Kevin Steinke maintains CRA Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRAI#NASDAQ">CRAI</a>) with a Outperform and raises the price target from $194 to $212.

News

Price Target

CRAI

Barrington Research Maintains Outperform on CRA Intl, Raises Price Target to $212

Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on Taboola.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBLA#NASDAQ">TBLA</a>) in the last three months.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $5.0, along with a high estimate of $5.00 and a low estimate of $5.00. Consistency is reflected as the current average remains at the same level as the previous average price target. 
<img src="https://www.benzinga.com/files/images/story/2024/1731081628_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of Taboola.com's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$5.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$5.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$5.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$5.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Mark Zgutowicz</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$5.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$5.00</td>
<td>$5.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Taboola.com. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Taboola.com compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Taboola.com's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Capture valuable insights into Taboola.com's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TBLA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Taboola.com analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Taboola.com</h2>
Taboola.com Ltd is a technology company that powers recommendations across the Open Web with an artificial intelligence-based, algorithmic engine. It partners with websites, devices, and mobile apps, collectively referred to as digital properties, to recommend editorial content and advertisements on the Open Web. Geographically it serves Israel, the United Kingdom, Germany, France, Rest of the world whilst it generates the majority of its revenue from the United States.
<h3>Taboola.com's Economic Impact: An Analysis</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Positive Revenue Trend: Examining Taboola.com's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 28.96% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Communication Services sector.
Net Margin: Taboola.com's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -1.0%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Taboola.com's ROE excels beyond industry benchmarks, reaching -0.42%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Taboola.com's ROA stands out, surpassing industry averages. With an impressive ROA of -0.26%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.21.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TBLA

Evaluating Taboola.com: Insights From 6 Financial Analysts

WIIM

RXST

RxSight shares are trading lower. The company reported Q3 financial results.

Oppenheimer analyst Suraj Kalia maintains Artivion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AORT#NYSE">AORT</a>) with a Outperform and raises the price target from $30 to $32.

AORT

Oppenheimer Maintains Outperform on Artivion, Raises Price Target to $32

ASPCU

Trading Halt: Halt status updated at 11:00:00 AM ET: Quotation Resumption: IPO Security - Released for Quotation

Oppenheimer analyst Colin Rusch maintains Array Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARRY#NASDAQ">ARRY</a>) with a Outperform and lowers the price target from $17 to $14.

ARRY

Oppenheimer Maintains Outperform on Array Technologies, Lowers Price Target to $14

Wedbush analyst Jay McCanless maintains Redfin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDFN#NASDAQ">RDFN</a>) with a Neutral and raises the price target from $8 to $10.

RDFN

Wedbush Maintains Neutral on Redfin, Raises Price Target to $10

Oppenheimer analyst Tyler Batory reiterates Apple Hospitality REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APLE#NYSE">APLE</a>) with a Outperform and raises the price target from $17 to $18.

Reiteration

APLE

Oppenheimer Reiterates Outperform on Apple Hospitality REIT, Raises Price Target to $18

The German State Criminal Police (LKA) has dismissed reports claiming OneCoin founder Ruja Ignatova was murdered, suggesting the notorious &#8220;Crypto Queen&#8221; &#8211; responsible for a $4 billion cryptocurrency fraud &#8211; may be alive and <a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39509963/u-s-offers-5m-reward-for-information-on-crypto-fraudster-ruja-ignatova">hiding in South Africa.</a>
What Happened: Ignatova, who made the FBI&#8217;s Ten Most Wanted Fugitives List in 2022, has been on the run since October 2017 when she fled from Sofia to Athens following her U.S. indictment on charges of wire fraud, money laundering, and securities fraud.
The U.S. State Department maintains a $5 million reward for information leading to her arrest.
LKA Düsseldorf, leading the German investigation, has debunked documents suggesting Ignatova was murdered in 2018 and disposed of in the Ionian Sea. 
&#8220;We assume or are working with the hypothesis that Ruja Ignatova is still alive,&#8221; stated LKA spokeswoman Sabine Dässel, as <a href="https://www.spiegel.de/netzwelt/web/onecoin-deutsche-ermittler-halten-todesmeldung-zu-kryptoqueen-ruja-ignatova-fuer-falsch-a-fc6cd492-c961-4aed-b3dc-f69324597b88">reported</a> by Der Spiegel.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41843928/bitcoin-etfs-saw-record-1-38-billion-inflows-on-thursday">Bitcoin ETFs Saw Record $1.38 Billion Inflows On Thursday</a>
The Bulgarian-born German national allegedly orchestrated one of history&#8217;s <a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39139647/was-crypto-queen-ruja-ignatova-murdered-by-a-bulgarian-crime-head">largest fraud schemes</a> through OneCoin Ltd., which she launched in 2014, marketing it as a &#8220;Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) killer.&#8221; 
By 2017, investors worldwide had lost over $4 billion through the fraudulent cryptocurrency investment scheme.
Investigators are now focusing on South Africa, particularly Cape Town&#8217;s wealthy districts, where security sources report possible sightings. 
The area&#8217;s connection to OneCoin deepened after a 2023 incident involving the murder of a Bulgarian criminal who allegedly planned to testify to U.S. investigators.
While some assets have been recovered, including $10 million from London property sales, most investor funds remain unaccounted for. 
What&#8217;s Next: The ongoing investigation into OneCoin&#8217;s collapse and its implications for cryptocurrency regulation will be a key topic at Benzinga&#8217;s <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event on Nov. 19, where industry experts will discuss fraud prevention and investor protection in digital assets.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41841793/bitcoin-ethereum-solana-rally-does-not-mean-all-cryptocurrencies-will-moon-10x-research">Bitcoin, Ethereum, Solana Rally Does Not Mean All Cryptocurrencies Will Moon: 10x Research</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

'Crypto Queen' Ruja Ignatova, OneCoin's $4 Billion Fraud Mastermind, Is Alive And In South Africa, German Police Suspects

Wedbush analyst Moshe Katri maintains Toast (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>) with a Outperform and raises the price target from $35 to $45.

TOST

Wedbush Maintains Outperform on Toast, Raises Price Target to $45

Oppenheimer analyst Colin Rusch maintains Albemarle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>) with a Outperform and lowers the price target from $171 to $170.

Oppenheimer Maintains Outperform on Albemarle, Lowers Price Target to $170

ADMA

ADMA Biologics shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 and FY25 revenue guidance.

IOVA

Iovance Biotherapeutics shares are trading lower. The company reported Q3 financial results.

Wedbush analyst Michael Pachter maintains Turtle Beach (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEAR#NASDAQ">HEAR</a>) with a Outperform and raises the price target from $19 to $20.

HEAR

Wedbush Maintains Outperform on Turtle Beach, Raises Price Target to $20

Wedbush analyst Scott Devitt maintains Pinterest (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>) with a Neutral and raises the price target from $37 to $38.

PINS

Wedbush Maintains Neutral on Pinterest, Raises Price Target to $38

Wedbush analyst Scott Devitt maintains Airbnb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) with a Outperform and raises the price target from $135 to $155.

ABNB

Wedbush Maintains Outperform on Airbnb, Raises Price Target to $155

Wedbush analyst Daniel Ives maintains Consensus Cloud Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCSI#NASDAQ">CCSI</a>) with a Outperform and raises the price target from $24 to $32.

CCSI

Wedbush Maintains Outperform on Consensus Cloud Solns, Raises Price Target to $32

Rivian Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) analysts are cautious on the short-term outlook for the electric vehicle company with supply chain concerns, after the company missed third-quarter revenue and <a href="https://www.benzinga.com/news/earnings/24/11/41825787/rivian-q3-earnings-highlights-revenue-eps-miss-ceo-confident-in-q4-gross-profit-r2-being-fundamenta">earnings per share estimates.</a>
The Rivian Analysts: 
<ul>
<li>Truist analyst Jordan Levy maintained a Hold rating on Rivian with a $12 price target.</li>
<li>Wedbush analyst Daniel Ives maintained an Outperform rating with a $20 price target.</li>
<li>Needham analyst Chris Pierce reiterated a Buy rating and lowered the price target from $18 to $14.</li>
<li>Piper Sandler analyst Alexander Potter maintained an Overweight rating and lowered the price target from $21 to $19.</li>
</ul>
Read Also: <a href="https://www.benzinga.com/markets/equities/24/11/41832998/rivian-draftkings-block-pinterest-and-tesla-why-these-5-stocks-are-on-investors-radars-today">Rivian, Draftkings, Block, Pinterest, And Tesla: Why These 5 Stocks Are On Investors&#8217; Radars Today</a>
Truist on RIVN: Proof of profitability for Rivian's R1 vehicle may be necessary to instill confidence in the R2 launch, Levy said in a new investor note.
"RIVN's third quarter results were mired by the company's previously reported component shortage, though a significant expected 4Q uptick in regulatory credit sales + realization of cost-down from Gen 2 models enabled the company to reiterate its 4Q positive GM (gross margin) target," Levy said.
The analyst said Rivian needs to demonstrate consistent profitability to help investors gain confidence.
Rivian's tailwind of resolving supply chain issues was not a surprise to investors, Levy added.
"While we are incrementally positive on the timeline reiteration for R2, we see the recent election results and the incoming administration being an overhang over the entire domestic EV market for the time being given the uncertainty."
Wedbush on RIVN: The electric vehicle company made progress and saw strong demand in the third quarter, but Ives said in a new investor note that there is more work ahead.
Ives said Rivian took two steps forward but one step back as the supply chain challenges hurt the company's plan to ramp up production.
"Rivian did not anticipate such large supply ramp challenges this quarter, however, it should be well sorted over the next few quarters as the company is still on track in terms of timing the R2 production launch," Ives said.
A supply partnership announced with LG on Thursday and the pending launch of the Volkswagen (OTC:<a class="ticker" href="https://www.benzinga.com/stock/VWAGY#OTC">VWAGY</a>) joint venture are "critical pieces" for the future of Rivian, Ives added.
"Although we still remain confident in the long-term Rivian vision, it will take some serious strides for the company to regain trust in the short-term vision in the eyes of the Street."
Needham on RIVN: Scale and margins are bearish talking points for the Rivian story, Pierce said in a new investor note.
"We continue to view RIVN as a long-term winner in the eventual ICE to EV transition, leaning on its ability to create a brand and produce vehicles that drive high levels of customer passion and satisfaction," Pierce said.
The analyst said R2 production enhancements are the key focus for 2025 with R2 production set to begin in the first half of 2026. Vehicle profitability for the R2 is expected to be reached faster than the R1 and will be a key factor to watch, the analyst added.
The analyst also highlighted a joint venture with Volkswagen expected to close in the fourth quarter.
"RIVN's balance sheet has been significantly strengthened the Volkswagen announcement, removing any additional equity needs vs our prior model, allowing for a higher level of investor patience."
Piper Sandler on RIVN: The third-quarter results and commentary had no surprises, leading to increasing importance for the joint venture with Volkswagen closing as the next catalyst, Potter said in a new investor note.
"The stock has faltered recently, partially due to slower production, and partially (in our view) because a JV with Volkswagen has yet to be finalized," Potter said.
The analyst said the joint venture terms could continue to be a story in the coming weeks and could see Rivian's valuation expand.
"We will review our model once the JV terms are announced."
RIVN Price Action: Rivian stock is down 0.48% to $10.00 on Friday, versus a 52-week trading range of $8.26 to $24.62. Rivian stock is down 51% year-to-date in 2024.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41784487/rivian-lucid-stocks-sink-after-trump-win-whats-driving-bearish-move">Rivian, Lucid Stocks Sink After Trump Win: What&#8217;s Driving Bearish Move?</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Trading Ideas

RIVN

VWAGY

Rivian Stock 'Long-Term Winner' In Gas-To-Electric Transition: Analyst

DraftKings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) stock initially traded lower on Friday but reversed course and began moving higher after the company reported third-quarter earnings and lowered its guidance for the 2024 fiscal-year after the bell <a href="https://www.benzinga.com//node/41826834">on Thursday</a>.
The Details: In the report, DraftKings reported a loss of 17 cents per share, beating analyst estimates of a loss of 42 cents per share. Furthermore, the company reported sales of $1.09 billion, missing analyst estimates of $1.11 billion. The reported sales figure represents a 38.6% year-over-year increase.
The company announced an increase in Monthly Unique Payers (MUPs) to 3.6 million, a growth of 55% year-over-year. It also reported Average Revenue per MUPs (ARPMUP) of $103, a 10% decrease compared to the same period last year.
&#8220;We achieved healthy results across our core value drivers in the&nbsp;third quarter&nbsp;with efficient customer acquisition and promotional reinvestment as well as improvement in our structural sportsbook hold percentage,&#8221; said Alan Ellingson, DraftKings&#8217; CFO. 
DraftKings revised its outlook for the 2024 fiscal-year. Specifically, it lowered its revenue guidance from between $5.05 billion and $5.25 billion to between $4.85 billion and $4.95 billion versus analyst estimates of $5.13 billion.
The company also introduced guidance for the 2025 fiscal-year. It anticipates revenue between $6.2 billion and $6.5 billion and adjusted EBITDA between $900 million and $1.0 billion.
Related Link: <a href="https://www.benzinga.com/news/24/11/41808861/whats-going-on-with-palantir-stock-thursday">What&#8217;s Going On With Palantir Stock Thursday?</a>
DKNG Price Action: At the time of publication, DraftKings shares are moving 5.05% higher at $40.95 , according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Photo via Shutterstock

Movers

DKNG

What's Going On With DraftKings Stock Friday?

Arbutus Biopharma (ABUS) has released an update. Arbutus Biopharma is set to showcase promising clinical data on its RNAi therapeutic, imdusiran, a...

Arbutus Biopharma Highlights Imdusiran's Potential in Hepatitis B

Tourlite Capital Q3 2024 Investor Letter

Arbutus Biopharma (ABUS) has released an update. Arbutus Biopharma is set to release its third quarter 2024 financial results and provide a corpora...

Arbutus Biopharma to Announce Q3 2024 Results

Arbutus Biopharma Q3 2024 Earnings Preview

Here's the major earnings before the open tomorrow

Arbutus Biopharma (ABUS) has released an update. Arbutus Biopharma reported promising results from its Phase 2a trials for imdusiran, a potential t...

Arbutus Biopharma Reports Promising Clinical Trial Results

JMP Securities analyst Roy Buchanan reiterated a Buy rating on Arbutus Biopharma (ABUS – Research Report) today and set a price target of $5.00. Ro...

Arbutus Biopharma's Promising Clinical Developments and Strong Financial Position Justify Buy Rating

Arbutus Biopharma Corporation (ABUS) Q3 2024 Earnings Call Transcript

Keay Nakae, an analyst from Chardan Capital, maintained the Buy rating on Arbutus Biopharma (ABUS – Research Report). The associated price target i...

Promising Developments in Arbutus Biopharma's Pipeline Lead to Buy Rating and Increased Price Target

Chardan raised the firm's price target on Arbutus Biopharma (ABUS) to $4.50 from $4 and keeps a Buy rating on the shares after its Q3 results. The ...

Arbutus Biopharma price target raised to $4.50 from $4 at Chardan

ABUS

ADRNY

ATHM

AUDC

BMWYY

CELH

CLBT

CNDT

EHTH

ENOV

FOLD

FTAI

FTAIM

FTAIN

FTAIO

FTAIP

HENKY

IONS

LNTH

MCFT

MKTX

MOGO

NEON

OESX

PERI

PFGC

PRGO

ROIV

RPRX

SNDR

STWD

TCPC

TEVA

TRMB

URGN

VONOY

VRNOF

Health Care

Press Releases

General

Arbutus' Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure

Biotech

Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B

Treatment with Arbutus' Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels

Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update

Earnings

Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Arbutus to Participate in Two Upcoming Investor Conferences

Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference

Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024

Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update

Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Comments

Arbutus Biopharma

Arbutus Biopharma (ABUS) Opzioni

Arbutus Biopharma (NASDAQ:ABUS) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO